BioAtla (BCAB) Stock Forecast, Price Target & Predictions
BCAB Stock Forecast
BioAtla stock forecast is as follows: an average price target of $5.00 (represents a 187.36% upside from BCAB’s last price of $1.74) and a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.
BCAB Price Target
The average price target for BioAtla (BCAB) is $5.00 based on 1-year price targets from 1 Wall Street analysts in the past 3 months, with a price target range of $5.00 to $5.00. This represents a potential 187.36% upside from BCAB's last price of $1.74.
BCAB Analyst Ratings
According to 1 Wall Street analysts, BioAtla's rating consensus is 'Buy'. The analyst rating breakdown for BCAB stock is 0 'Strong Buy' (0.00%), 1 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
BioAtla Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| May 23, 2024 | Reni Benjamin | JMP Securities | $5.00 | $2.28 | 119.30% | 187.36% |
The latest BioAtla stock forecast, released on May 23, 2024 by Reni Benjamin from JMP Securities, set a price target of $5.00, which represents a 119.30% increase from the stock price at the time of the forecast ($2.28), and a 187.36% increase from BCAB last price ($1.74).
BioAtla Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $5.00 |
| Last Closing Price | $1.74 | $1.74 | $1.74 |
| Upside/Downside | -100.00% | -100.00% | 187.36% |
In the current month, the average price target of BioAtla stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to BioAtla's last price of $1.74. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| May 23, 2024 | JMP Securities | Outperform | Outperform | Hold |
BioAtla's last stock rating was published by JMP Securities on May 23, 2024. The company gave BCAB a "Outperform" rating, the same as its previous rate.
BioAtla Financial Forecast
BioAtla Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $250.00K | - | $250.00K |
| Avg Forecast | - | - | - | - | - | - | - | $15.00M | $1.50M | $466.67K | $333.33K | $250.00K | $4.60M | $10.98M | $170.00K |
| High Forecast | - | - | - | - | - | - | - | $15.00M | $1.50M | $466.67K | $333.33K | $250.00K | $4.60M | $10.98M | $170.00K |
| Low Forecast | - | - | - | - | - | - | - | $15.00M | $1.50M | $466.67K | $333.33K | $250.00K | $4.60M | $10.98M | $170.00K |
| # Analysts | - | - | - | - | 1 | 1 | 1 | 2 | - | - | - | - | 1 | 1 | 1 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.05% | - | 1.47% |
BioAtla's average Quarter revenue forecast for Mar 22 based on 0 analysts is $250.00K, with a low forecast of $250.00K, and a high forecast of $250.00K. BCAB's average Quarter revenue forecast represents a 0.00% decrease compared to the company's last Quarter revenue of $250.00K (Dec 21).
BioAtla EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | 1 | 1 | 2 | - | - | - | - | 1 | 1 | 1 |
| EBITDA | - | - | - | - | - | - | - | - | $-27.54M | $-25.48M | $-28.62M | $-23.94M | $-22.79M | $-22.47M | $-30.05M |
| Avg Forecast | - | - | - | - | - | - | - | $-3.00M | $-300.00K | $-93.33K | $-66.67K | $-25.33M | $-920.00K | $-2.20M | $-34.00K |
| High Forecast | - | - | - | - | - | - | - | $-3.00M | $-300.00K | $-93.33K | $-66.67K | $-20.26M | $-920.00K | $-2.20M | $-34.00K |
| Low Forecast | - | - | - | - | - | - | - | $-3.00M | $-300.00K | $-93.33K | $-66.67K | $-30.39M | $-920.00K | $-2.20M | $-34.00K |
| Surprise % | - | - | - | - | - | - | - | - | 91.81% | 272.99% | 429.27% | 0.95% | 24.78% | 10.23% | 883.94% |
undefined analysts predict BCAB's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than BioAtla's previous annual EBITDA (undefined) of $NaN.
BioAtla Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | 1 | 1 | 2 | - | - | - | - | 1 | 1 | 1 |
| Net Income | - | - | - | - | - | - | - | - | $-27.76M | $-25.41M | $-28.76M | $-24.16M | - | $-22.93M | $-30.38M |
| Avg Forecast | $-18.32M | $-22.42M | $-21.46M | $-20.73M | $-16.14M | $-17.61M | $-21.60M | $-38.21M | $-35.01M | $-38.60M | $-33.09M | $-25.66M | $-27.97M | $-31.06M | $-40.77M |
| High Forecast | $-18.32M | $-22.42M | $-21.46M | $-20.73M | $-16.14M | $-11.07M | $-21.60M | $-32.03M | $-35.01M | $-38.60M | $-33.09M | $-20.53M | $-27.97M | $-31.06M | $-40.77M |
| Low Forecast | $-18.32M | $-22.42M | $-21.46M | $-20.73M | $-16.14M | $-24.16M | $-21.60M | $-41.58M | $-35.01M | $-38.60M | $-33.09M | $-30.79M | $-27.97M | $-31.06M | $-40.77M |
| Surprise % | - | - | - | - | - | - | - | - | 0.79% | 0.66% | 0.87% | 0.94% | - | 0.74% | 0.75% |
BioAtla's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. BCAB's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
BioAtla SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | 1 | 1 | 2 | - | - | - | - | 1 | 1 | 1 |
| SG&A | - | - | - | - | - | - | - | - | $6.69M | $6.34M | $8.34M | $7.42M | $30.04M | $7.14M | $15.86M |
| Avg Forecast | - | - | - | - | - | - | - | $545.44M | $54.54M | $16.97M | $12.12M | $9.09M | $167.27M | $399.26M | $6.18M |
| High Forecast | - | - | - | - | - | - | - | $545.44M | $54.54M | $16.97M | $12.12M | $9.09M | $167.27M | $399.26M | $6.18M |
| Low Forecast | - | - | - | - | - | - | - | $545.44M | $54.54M | $16.97M | $12.12M | $9.09M | $167.27M | $399.26M | $6.18M |
| Surprise % | - | - | - | - | - | - | - | - | 0.12% | 0.37% | 0.69% | 0.82% | 0.18% | 0.02% | 2.57% |
BioAtla's average Quarter SG&A projection for Dec 23 is $545.44M, based on 2 Wall Street analysts, with a range of $545.44M to $545.44M. The forecast indicates a 8057.91% rise compared to BCAB last annual SG&A of $6.69M (Dec 22).
BioAtla EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | 1 | 1 | 2 | - | - | - | - | 1 | 1 | 1 |
| EPS | - | - | - | - | - | - | - | - | $-0.58 | $-0.68 | $-0.77 | $-0.65 | - | $-0.68 | $-0.90 |
| Avg Forecast | $-0.38 | $-0.47 | $-0.45 | $-0.43 | $-0.33 | $-0.37 | $-0.45 | $-0.79 | $-0.73 | $-0.80 | $-0.69 | $-0.66 | $-0.58 | $-0.64 | $-0.85 |
| High Forecast | $-0.38 | $-0.47 | $-0.45 | $-0.43 | $-0.33 | $-0.23 | $-0.45 | $-0.66 | $-0.73 | $-0.80 | $-0.69 | $-0.66 | $-0.58 | $-0.64 | $-0.85 |
| Low Forecast | $-0.38 | $-0.47 | $-0.45 | $-0.43 | $-0.33 | $-0.50 | $-0.45 | $-0.86 | $-0.73 | $-0.80 | $-0.69 | $-0.66 | $-0.58 | $-0.64 | $-0.85 |
| Surprise % | - | - | - | - | - | - | - | - | 0.80% | 0.85% | 1.12% | 0.99% | - | 1.06% | 1.06% |
According to undefined Wall Street analysts, BioAtla's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to BCAB previous annual EPS of $NaN (undefined).
BioAtla Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| PMVP | PMV Pharmaceuticals | $1.50 | $24.75 | 1550.00% | Buy |
| IPSC | Century Therapeutics | $1.46 | $20.00 | 1269.86% | Buy |
| ANTX | AN2 Therapeutics | $1.02 | $8.75 | 757.84% | Buy |
| PASG | Passage Bio | $0.70 | $6.00 | 757.14% | Buy |
| AVTE | Aerovate Therapeutics | $1.90 | $13.00 | 584.21% | Hold |
| STTK | Shattuck Labs | $3.50 | $12.00 | 242.86% | Buy |
| BCAB | BioAtla | $1.74 | $5.00 | 187.36% | Buy |
| RZLT | Rezolute | $4.35 | $12.50 | 187.36% | Buy |
| ACRV | Acrivon Therapeutics | $8.08 | $21.50 | 166.09% | Buy |
| ERAS | Erasca | $2.86 | $7.00 | 144.76% | Buy |
| FHTX | Foghorn Therapeutics | $7.53 | $18.00 | 139.04% | Buy |
| NAUT | Nautilus Bio | $2.55 | $6.00 | 135.29% | Buy |
| OLMA | Olema Pharmaceuticals | $11.83 | $27.00 | 128.23% | Buy |
| CCCC | C4 Therapeutics | $5.40 | $11.33 | 109.81% | Hold |
| DSGN | Design Therapeutics | $4.67 | $9.67 | 107.07% | Buy |
| ADAG | Adagene | $2.61 | $5.00 | 91.57% | Buy |
| NRIX | Nurix Therapeutics | $23.33 | $27.57 | 18.17% | Buy |
| KYMR | Kymera Therapeutics | $45.40 | $51.10 | 12.56% | Buy |
| IKNA | Ikena Oncology | $1.69 | $1.33 | -21.30% | Buy |
| GRCL | Gracell Bio | $10.25 | $6.00 | -41.46% | Buy |
BCAB Forecast FAQ
Is BioAtla a good buy?
Yes, according to 1 Wall Street analysts, BioAtla (BCAB) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 100.00% of BCAB's total ratings.
What is BCAB's price target?
BioAtla (BCAB) average price target is $5 with a range of $5 to $5, implying a 187.36% from its last price of $1.74. The data is based on 1 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will BioAtla stock go up soon?
According to Wall Street analysts' prediction for BCAB stock, the company can go up by 187.36% (from the last price of $1.74 to the average price target of $5), up by 187.36% based on the highest stock price target, and up by 187.36% based on the lowest stock price target.
Can BioAtla stock reach $3?
BCAB's average twelve months analyst stock price target of $5 supports the claim that BioAtla can reach $3 in the near future.
What are BioAtla's analysts' financial forecasts?
BioAtla's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-55.352M (high $-48.81M, low $-61.894M), average SG&A $0 (high $0, low $0), and average EPS is $-1.148 (high $-1.012, low $-1.284). BCAB's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-82.93M (high $-82.93M, low $-82.93M), average SG&A $0 (high $0, low $0), and average EPS is $-1.72 (high $-1.72, low $-1.72).
Did the BCAB's actual financial results beat the analysts' financial forecasts?
Based on BioAtla's last annual report (Dec 2021), the company's revenue was $250K, which missed the average analysts forecast of $15.75M by -98.41%. Apple's EBITDA was $-94.759M, beating the average prediction of $-3.15M by 2908.23%. The company's net income was $-94.712M, missing the average estimation of $-99.8M by -5.10%. Apple's SG&A was $38.42M, missing the average forecast of $572.71M by -93.29%. Lastly, the company's EPS was $-2.74, beating the average prediction of $-2.07 by 32.37%. In terms of the last quarterly report (Dec 2021), BioAtla's revenue was $250K, missing the average analysts' forecast of $4.6M by -94.57%. The company's EBITDA was $-22.794M, beating the average prediction of $-920K by 2377.61%. BioAtla's net income was $0, missing the average estimation of $-27.971M by -100.00%. The company's SG&A was $30.04M, missing the average forecast of $167.27M by -82.04%. Lastly, the company's EPS was $0, missing the average prediction of $-0.58 by -100.00%